Talia Atlas

Icahn School of Medicine at Mount Sinai

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Florian Krammer

Icahn School of Medicine at Mount Sinai

Raffael Nachbagauer

Icahn School of Medicine at Mount Sinai

Peter Palese

Icahn School of Medicine at Mount Sinai

Randy A. Albrecht

Icahn School of Medicine at Mount Sinai

Angela Choi

Moderna Therapeutics (United States)

Adolfo García‐Sastre

Icahn School of Medicine at Mount Sinai

Alicia Solórzano

Icahn School of Medicine at Mount Sinai

Paul Bunduc

Icahn School of Medicine at Mount Sinai

Francesco Berlanda-Scorza

Program for Appropriate Technology in Health

Madhusudan Rajendran

Rochester Institute of Technology

Cooperative Institutions

Icahn School of Medicine at Mount Sinai

Czech Academy of Sciences, Institute of Microbiology

Mount Sinai Hospital

U.S. National Poultry Research Center

Moderna Therapeutics (United States)

Mount Sinai Hospital

Mount Sinai Health System

Pfizer (United States)

Rutgers, The State University of New Jersey

Virginia–Maryland College of Veterinary Medicine

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies

npj Vaccines (2017)

Raffael Nachbagauer Wen‐Chun Liu Angela Choi Teddy John Wohlbold Talia Atlas

Influenza viruses evade human adaptive immune responses due to continuing antigenic changes. This makes it necessary to re-formulate and re-administer current seasonal influenza vaccines on an annual basis. Our pan-influenza vaccination approach attempts to redirect antibody responses from the variable, immuno-dominant hemagglutinin head towards the conserved-but immuno-subdominant-hemagglutinin stalk. The strategy utilizes sequential immunization with chimeric hemagglutinin-based vaccines expressing exotic head domains, and a conserved hemagglutinin stalk. We compared a live-attenuated influenza virus prime followed by an inactivated split-virus boost to two doses of split-virus vaccines and assessed the impact of adjuvant on protection against challenge with pandemic H1N1 virus in ferrets. All tested immunization regimens successfully induced broadly cross-reactive antibody responses. The combined live-attenuated/split virus vaccination conferred superior protection against pandemic H1N1 infection compared to two doses of split-virus vaccination. Our data support advancement of this chimeric hemagglutinin-based vaccine approach to clinical trials in humans.

Pandemic

H5N1 genetic structure

10.1038/s41541-017-0026-4

Cite

Citations (129)

Ebola Virus Disease: The 2014 West African Outbreak and Epidemic Preparedness in the United States

Talia Atlas

Preparedness

Source

Cite

Citations (0)

A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in ferrets